Monitor for any subsequent 13D conversion or stake increases by Spruce Street, though the passive certification makes activist intent unlikely. The accumulation of passive stakes by multiple funds post-offering suggests institutional interest in Yarrow's Phase 2a Graves disease trial, with topline results expected in H2 2027.
Drug in focus
YARW drug pipeline →YB-101
◆ Mixed Named in this SC 13G- Impact
- Phase
- Phase 2a/2b (dosing initiated ~July 27, 2026); Phase 1 SAD in thyroid eye disease previously reported
- Time to market
- Unknown — mid-stage. If the Phase 2a/2b trial succeeds and later registrational studies follow, approval would be several years away (late 2020s at the earliest); the company currently has no approved products.
- Next catalyst
- None dated
What to watchYB-101 is a Phase 2a/2b, single-asset bet at a company (Nasdaq: YARW, formerly VYNE) that just closed a reverse merger, raised ~$200M, and began dosing the pivotal-to-next-stage trial, but the defining data readout is not expected until 2H 2027. A non-medical investor should treat YARW as a speculative, liquidity-thin clinical stock: watch for interim Phase 2a/2b data, the exact readout date, and any competitive readouts from anti-FcRn/IgG-degrading drugs in Graves'/thyroid eye disease.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spruce Street Capital LP filed a Schedule 13G disclosing a 6.4% passive stake in Yarrow Bioscience, representing 607,382 shares as of September 30, 2026. This is a new filing by Spruce Street, adding to a series of recent 13G filings by other institutional investors (Bellevue Group at 10.6%, Invus Global at 7.2%) following Yarrow's September 2026 equity offering. The passive certification and hedge fund identity suggest a routine investment, not an activist precursor.
Key Financial Metrics
Key Facts
- Spruce Street Capital LP disclosed a 6.4% passive stake in Yarrow Bioscience, representing 607,382 shares
- Stake based on 9,437,693 shares outstanding as of September 14, 2026, after the company's public offering
- Filing certifies passive intent under Rule 13d-1(b), with no intention to influence control
- This is a new 13G filing, not an amendment to a prior filing
- Spruce Street is a hedge fund based in New York, NY
Financial Impact
6.4% stake valued at approximately $10.8M based on $168M market cap
Risk Factors
- Passive certification could be converted to active (13D) if Spruce Street changes intent, though no indication of this
- Concentration of institutional ownership may increase stock volatility on trial results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000902664-26-004528 |
| Document: 0000902664-26-004528-index-headers.html | 0000902664-26-004528 |
| Document: 0000902664-26-004528-index.html | 0000902664-26-004528 |
| Document: 0000902664-26-004528.txt | 0000902664-26-004528 |
Track record
13 reports on YARW
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 17, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.20 Now $14.27 +0.49% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $13.93 Now $14.27 +2.44% settles Dec 16
- Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $15.44 Now $14.27 −7.58% settles Dec 15
- Nov 16, 20261d ago SC 13G Neutral 3/10 Entry $18.20 Now $14.27 −21.59% settles Dec 15
- Nov 16, 20261d ago SC 13G/A Neutral 3/10 Entry $18.03 Now $14.27 −20.85% settles Dec 15
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $17.35 Now $14.27 −17.75% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Viewing Entry $18.03 Now $14.27 −20.85% settles Dec 15
- Nov 12, 20265d ago 8-K Neutral 4/10 Entry $19.63 Now $14.27 −27.31% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers